Week in Review: Akeso Stages $335 Million HK IPO for Mono-/Bi-Specific Antibodies
publication date: Apr 25, 2020
Deals and Financings
• AkesoBio of Zhongshan staged a $335 million Hong Kong IPO to support its novel mono- and bi-specific antibodies, and climbed 50% higher in its first trading session;
• Hansoh, a Shanghai Pharma, in-licensed greater China rights to a novel small molecule anti-viral from US-based NiKang in a deal potentially worth over $100 million;
• APTBIO, a Shanghai proteomic company, completed a $28 million Series A financing, to support biologic drug discovery services based on mass spectrometry;
• New Horizon Health of Hangzhou completed a $20 million Series D financing for its early-stage cancer screening products;
• Guangzhou Magpie Pharmaceutical closed a $14 million Pre-C funding round for its portfolio of novel drugs based on modernized formulations of proven TCM drugs;
• ChosenMed Technology of Beijing raised "hundreds of millions of yuan" in a Series B round for its oncology precision medicine services;
Trials and Approvals
• Suzhou Innovent announced China's NMPA will review its sNDA for a combination regimen including the company's PD-1 antibody, Tyvyt®, to treat non-small cell lung cancer;
• CStone Pharma of Suzhou announced that its avapritinib NDA, a precision therapy aimed at treating GIST, was accepted for review;
• Harbour BioMed dosed the first patient in a China Phase Ib/IIa trial of its anti-FcRn antibody to treat an autoimmune disease, neuromyelitis optica spectrum disorder;
• Mabspace Biosciences (Suzhou) was cleared by the US FDA to start trials of its novel humanized Claudin 18.2 mAb in patients with metastatic solid tumors;
Coronavirus Outbreak
• The US FDA has granted emergency use authorization for a COVID-19 RT-PCR detection kit developed by Shanghai Fosun Pharma;
• Beijing's Sinovac Biotech announced positive efficacy and safety from animal tests of its PiCoVacc chemically inactivated COVID-19 vaccine candidate,
Stock Symbols: (HK: 9926) (HK; 3692) (HK: 01801) (HK: 2616) (SHA: 600196; HK: 02196) (NSDQ: SVA)
Share this with colleagues:
Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?
If you are already a subscriber, please login.
If you believe you should have received this message in error, please contact us.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
